Why give low‑molecular‑weight heparin (enoxaparin) in acute coronary syndrome?

Why Give Enoxaparin (LMWH) in Acute Coronary Syndrome

Enoxaparin is given in ACS to prevent thrombotic complications—including recurrent ischemia, myocardial infarction, and death—by providing predictable, effective anticoagulation that reduces both ischemic events and, in certain contexts, bleeding complications compared to unfractionated heparin.

Core Rationale for Anticoagulation in ACS

In ACS, atherosclerotic plaque rupture or erosion triggers thrombus formation, creating ongoing thrombotic risk. Anticoagulation is mandatory in addition to antiplatelet therapy for all ACS patients, regardless of whether you're pursuing an invasive or conservative strategy 1. The goal is to inhibit thrombin generation and prevent propagation of coronary thrombus during the acute phase and through any revascularization procedures.

Why Enoxaparin Specifically?

Pharmacologic Advantages Over UFH

Enoxaparin offers several practical and clinical benefits:

• Predictable anticoagulation: Fixed weight-based dosing (1 mg/kg SC every 12 hours) without need for aPTT monitoring 1, 2
• Superior bioavailability: More consistent absorption and effect compared to UFH's variable response 3
• Lower risk of heparin-induced thrombocytopenia: Reduced incidence of this serious complication 1
• Ease of administration: Subcutaneous dosing allows continuation outside the ICU and facilitates early discharge strategies

Clinical Efficacy Evidence

For STEMI with fibrinolytic therapy, enoxaparin is the Class I, Level A recommended anticoagulant when an invasive approach is not planned 1. It reduces ischemic events more effectively than UFH in this setting and should be continued for the duration of hospitalization (maximum 8 days) or until revascularization 1.

For NSTE-ACS, the evidence is more nuanced. While enoxaparin has been extensively studied and shows efficacy, multiple meta-analyses have not demonstrated compelling superiority over UFH in the current era of early invasive management and dual antiplatelet therapy 2. The 2025 ACC/AHA guidelines give enoxaparin a Class 2b recommendation (may be considered) as an alternative to UFH at the time of PCI to reduce ischemic events 2, 1.

Practical Dosing Considerations

Initial Therapy

• Standard dose: 1 mg/kg SC every 12 hours 1, 2
• Renal impairment (CrCl <30 mL/min): Reduce to 1 mg/kg SC once daily 1, 2
• With fibrinolysis in STEMI:
  • Age <75 years: 30 mg IV bolus, then 1 mg/kg SC every 12 hours (max 100 mg for first 2 doses)
  • Age ≥75 years: NO bolus, 0.75 mg/kg SC every 12 hours (max 75 mg for first 2 doses) 1, 2

Transitioning to PCI

This is where many clinicians get confused. The timing of the last enoxaparin dose determines your approach 1, 2:

• Last dose <8 hours ago: Give NO additional enoxaparin
• Last dose 8-12 hours ago OR only 1 dose given: Give 0.3 mg/kg IV bolus
• No prior enoxaparin: Give 0.5-0.75 mg/kg IV bolus

Critical Caveats and Pitfalls

Do NOT Switch Between Anticoagulants

Never switch from enoxaparin to UFH or vice versa—this significantly increases bleeding risk 4. Once you start enoxaparin, continue it through the patient's course.

Renal Function Assessment is Mandatory

Calculate creatinine clearance before initiating enoxaparin, particularly in elderly patients where renal impairment is common 5. Failure to dose-adjust in renal dysfunction increases bleeding risk substantially.

Bleeding vs. Ischemic Trade-offs

While enoxaparin reduces ischemic events, recent data in the early invasive era suggest the superior efficacy over UFH must be balanced against a modest increase in major bleeding complications 3. This is particularly relevant in:

• Elderly patients (≥75 years)
• Those with renal impairment
• Patients receiving aggressive antiplatelet therapy including GP IIb/IIIa inhibitors

The 2025 guidelines acknowledge this by downgrading enoxaparin to Class 2b for PCI support in NSTE-ACS, reflecting equipoise between efficacy and safety 2, 1.

When NOT to Use Enoxaparin

Consider alternatives (UFH or bivalirudin) in:

• Severe renal impairment (CrCl <30 mL/min)—though dose-adjusted enoxaparin is still an option
• Known heparin-induced thrombocytopenia (use bivalirudin or argatroban instead) 1
• Situations requiring rapid reversal (UFH can be reversed with protamine; enoxaparin reversal is incomplete)

Comparison with Alternatives

Fondaparinux showed similar ischemic efficacy to enoxaparin with reduced bleeding in OASIS-5, but carries a Class 3 Harm recommendation for PCI support due to catheter thrombosis risk (0.9% vs 0.3% with enoxaparin) 1, 2.

Bivalirudin has emerged as a strong alternative, particularly in STEMI undergoing primary PCI, where it received a Class I recommendation for reducing mortality and bleeding when used with a 2-4 hour post-PCI infusion 2, 1.

Bottom Line Algorithm

For STEMI with fibrinolysis (no immediate PCI planned):

• Use enoxaparin as first-line anticoagulant (Class I, Level A)
• Dose based on age and renal function as above
• Continue through hospitalization or until revascularization

For NSTE-ACS or STEMI with planned PCI:

• Enoxaparin is a reasonable alternative to UFH (Class 2b)
• Consider patient-specific factors: renal function, bleeding risk, timing of PCI
• If using enoxaparin, dose appropriately for PCI timing
• Do not switch anticoagulants mid-course

In all cases: Calculate CrCl, adjust for renal dysfunction, and maintain consistency in anticoagulant choice throughout the patient's acute management 1, 2, 1.